Urology Medical News about prostate cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Monoclonal antibodies show antitumor efficacy in prostate cancer
Urology Times, 11/04/09

Kuznar W – Median composite time to disease progression was 4.8 months. Nine patients were free of progression at 6 or more months. Of 28 patients evaluable for PSA response, one had a response defined as a decrease in PSA of at least 50% from baseline that was confirmed at least 3 weeks later. Three other patients had less than 50% decrease in PSA.

<< Previous
Flexible cystoscopes: Urologists prefer digital type

Next >>
CT can detect rare post-percutanous nephrolithotomy complications

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09 Relevance Score: 72%

Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09 Relevance Score: 71%

A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09 Relevance Score: 71%

Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09 Relevance Score: 71%

Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09 Relevance Score: 71%